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CaMDR1 encodes a major facilitator superfamily (MFS) protein in Candida albicans whose expression has been 
linked to azole resistance and which is frequently encountered in this human pathogenic yeast. In this report  
we have overexpressed CaMdr1p in Sf9 insect cells and demonstrated for the first time that it can mediate 
methotrexate (MTX) and fluconazole (FLC) transport. MTX appeared to be a b tter substrate for CaMdr1p 
among these two tested drugs. Due to severe toxicity of these drugs to insect cells, further characterization of 
CaMdr1p as a drug transporter could not be done with this system. Therefore, as an alternative, CaMdr1p and 
Cdr1p, which is an ABC protein (ATP binding cassette) also involved in azole resistance in C. albicans, were  
independently expressed in a common hypersensitive host JG436 of Saccharomyces cerevisiae. This allowed  
a better comparison between the functionality of the two export pumps. We observed that while both FLC 
and MTX are effluxed by CaMdr1p, MTX appeared to be a poor substrate for Cdr1p. JG436 cells expressing 
Cdr1p thus conferred resistance to other antifungal drugs but remained hypersensitive to MTX. Since MTX is 
preferentially transported by CaMdr1p, it can be used for studying the function of this MFS protein.  
1. Introduction 
The opportunistic dimorphic fungus Candida albicans is a 
major cause of life threatening fungal infections in  
humans, and is predominantly rampant in immunocom-
promized individuals. C. albicans infections are treated 
with antifungal agents, particularly with the triazole  
derivative fluconazole (FLC). In order to combat the  
effects of antifungals, Candida has evolved a variety of 
mechanisms to acquire resistance to these drugs (Cannon 
et al 1998; Marichal 1999; White et al 1998). The resis-
tance to azoles in C. albicans primarily occurs through  
an alteration or an overexpression of the 14a-lanosterol 
demethylase (P45014DM) involved in ergosterol biosyn- 
thesis. Recent identification of ATP binding cassette 
(ABC) proteins viz. Cdr1p and Cdr2p (Candida drug  
resistance) (Prasad 1995; Sanglard et l 1997) and their 
overexpression in azole resistant clinical isolates has led 
to the suggestion that these transporters could represent 
another mechanism involved in multidrug resistance 
(MDR) scenario of C. albicans (Albertson et al 1996; 
Krishnamurthy et al 1998a). 
 Fling et al (1991) had earlier identified the CaMDR1 
gene in C. albicans which encodes a major facilitator  
superfamily (MFS) pump and conferred resistance to  
benomyl and methotrexate (MTX) (Ben Yaacov et al 
1994; Gupta 1998). Recently, the overexpression of 
CaMDR1 has also been linked to azole resistance in C. 
albicans (White et al 1998). On the basis of the complete 
yeas  genome sequence, at least 28 MFS proteins have 
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been identified in Saccharomyces cerevisiae (Goffeau  
et al 1997) and sequencing efforts of Candida genome 
reveal that this pathogen could also have similar number 
of MFS proteins. In spite of the existence of a large num-
ber of these proteins, only a few have been associated 
with drug resistance, while a vast majority as MDR  
determinants remains unknown. Although the molecular 
basis of drug resistance in Candida is not very clear, but 
accumulated evidences suggest that MDR is a multifacto-
rial phenomenon where a combination of mechanisms 
could contribute to azole resistance (Bossche et al 1994; 
White et al 1998). Here we rport the overexpression of 
CaMdr1p in Sf9 insect cells for the first time, to show that 
it could transport MTX and FLC and that MTX is much 
preferred substrate of CaMdr1p over FLC. 
2. Materials and methods 
2.1 Materials 
The chemicals used were from Sigma Chemical (USA). 
All media components were purchased either from Difco 
(USA) or HiMedia (India). FLC was kindly provided  
by Pfizer Ltd., Sandwich, Kent, UK. The [3H]FLC and 
[3H]MTX were obtained from Amersham (UK). 
2.2 Yeast strains and growth media 
S. cerevisiae strain JG436, which lacks a functional PDR5 
gene (pleiotropic drug resistance) and is hypersensitive to 
drugs (Mat a, PDR5::Tn5, leu2, met5, ura3-52, mak71, 
KRB1) was a kind gift from Dr J Golin, Catholic University 
of America, Washington DC, USA. JG436 was transformed 
with plasmid pNC39 (carrying CaMDR1) and plasmid 
pS12 (carrying CDR1) that were obtained from C. albi-
cans genomic library as described earlier (Prasad et l 
1995; Gupta et al 1998). It should be noted that both  
the genes had a common vector background of pYEUra3. 
The resulting JG436 transformants were designated as 
JGCaMDR1 and JGCDR1. The strains were grown on 
YNB w/o amino acids with the respective supplements as 
described earlier (Prasad et al1995). 
2.3 Cloning of CaMDR1 in Sf9 cells 
CaMDR1 was cloned into pBacPAK8TM (Clontech,  
USA) as a 2×1 kb EcoRV fragment of pNC39 using stan-
dard recombinant techniques resulting in a plasmid 
pVGAcCaMDR1. Sf9 cells were co-transfected with wild 
type Autographa californica nuclear polyhedrosis virus 
(AcNPV) DNA and pVGAcCaMDR1 using LipofectinTM 
(Clontech, USA) as described earlier (Krishnamurthy  
et al 1998b). The resulting virus was designated as  
vAcCaMDR1. Recombinant baculoviruses were identified 
by plaque assay and the integration of CaMDR1 at the 
polh locus of vAcCaMDR1 was confirmed by Southern 
hybridisation using [32P]-labelled CaMDR1 specific 
probe. The recombinant virus was amplified to 108 plaque 
forming units ml–1 for further studies. 
2.4 Drug transport in virus infected insect cells 
To study the transport of FLC, 0×5 × 106 Sf9 cells were 
seeded in a 24-well culture plate. The cells were infected 
with recombinant virus, vAcCaMDR1 and cells infected 
with wild type virus, AcNPV were taken as control. After 
48 h post infection, the cells that adhere to the cul ure 
plate were washed with PBS (pH 7×4). [3H]FLC (0×7 TBq 
mmol–1) was then added at a final concentration of 
100 nM. At different time intervals, the cells were wash d 
with ice cold PBS and lysed with 0×5 M NaOH. For study-
ing MTX transport [3H]MTX (0×2 TBq mmol–1) was 
added at a final concentration of 25 mM. The total radio-
activity accumulated in cells was measured in liquid sci-
tillation counter using cocktail-T (Spectrochem, India) 
scintillation liquid. The protein content of the lysed cells 
was quantitated by a modified Bradford method (Pande 
and Murthy 1994). 
2.5 Antifungal susceptibility testing 
Susceptibility of yeast isolates to FLC, MTX, cyclo-
heximide (CYH) and benomyl (BEN) were det rmined by 
micro dilution test in SD–URA media as described previ-
ously (Talibi and Raymond 1999). The MIC test end point 
was defined as the lowest drug concentration, which gave 
> 80% inhibition of growth compared with drug free controls. 
2.6 Radio-labelled drug accumulation and energy  
dependence in S. cerevisiae cells 
Accumulation of labelled drugs in yeast cells was deter-
mined essentially as described previously by Smriti et al 
(1999). For competition experiments, 100 folds excess  
of cold drugs (2×5 mM for [3H]MTX and 10 mM for 
[3H]FLC competition) viz BEN, CYH, FLC and MTX 
were added to the cell suspension (5 × 108 cells ml–1) 
5 min before the addition of 100 nM [3H]FLC or 25 mM 
[3H]MTX. Similarly, inhibitors like sodium azide (10 mM) 
nd sodium orthovanadate (100 mM) were also added 
5 min before the commencement of the transport. The 
accumulation of drug was meaured at 30 min time point. 
The differences in intracellular accumulation of radio-
labelled drug between JGCaMDR1 cells incubated with 
and without competitor were calculated as per cent inhibi-
tion of efflux. 
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3. Results and discussion 
3.1 Cloning of CaMDR1 in baculovirus  
expression system 
Although ABC transport proteins have been extensively 
studied in the context of active drug efflux (Marichal 
1999; White t al 1998), MFS proteins of C. albicans 
have not received similar attention. In the present work 
we have studied drug transport mediated by a MFS pro-
tein, CaMdr1p, by expressing it for the first time in a 
baculovirus system which has been increasingly used for 
high level expression of foreign genes in insect cell lines 
Spodoptera frugiperda (Sf9). CaMDR1 was cloned into 
pBacPAK8TM (Clontech, USA) baculovirus shuttle vec or
as described in § 2. The resulting recombinant plasmid 
pVGAcCaMDR1 included full ORF of CaMDR1 preceded 
by ~ 110 bp of 5¢-untranslated region under the transcrip-
tional control of very strong polyhedrin ( polh) promoter. 
Homologous recombination in vivo between the AcNPV 
sequences in the transfer vector and the AcNPV geno- 
mic sequence generated a recombinant baculovirus  
vAcCaMDR1, which was confirmed by Southern hybri-
dization (figure 1). 
 The expression of CaMdr1p in Sf9 cells was checked 
using [35S]methionine labelling as described earlier 
(Krishnamurthy et al 1998b). The time course analysis of 
CaMdr1p synthesis in vAcCaMDR1 infected Sf9 cells 
revealed that it was maximally expressed at 48 h post 
infection and accordingly this time point was selected for 
subsequent transport experiments (data not shown). 
3.2 CaMdr1p mediates FLC and MTX transport  
in insect cells 
Although CaMDR1 has been linked to drug resistance, its 
mechanism of action remains poorly understood. The 
overexpressed CaMdr1p in baculovirus system provided 
an opportunity to understand its mechanism of drug trans-
port. We selected two drugs FLC and MTX for transport 
studies since these drugs are known to transcriptionally 
activate CaMDR1 (Albertson et al 1996; Gupta et al 
1998). The choice of concentration of FLC selected for 
transport assay was based on a previous report (Smriti  
et al 1999). However, for MTX, a concentration depend-
ent transport assay revealed that 25 mM concentration was 
optim m (data not shown). It is evident from figure 2a,b 
that insect cells infected with vAcCaMDR1 showed  
significantly reduced accumulation of FLC and MTX as 
compared to cells infected with wild type AcNPV virus. 
This lower accumulation of MTX suggested that most of 
Figure 1. Cloning of CaMDR1 in pBacPak8 vector and its integration into polh locus of AcNPV genome. (a) Schematic diagram 
depicting construction of pVGAcCaMDR1. A 2×1 kb EcoRV fragment of pNC39 harbouring CaMDR1, was subcloned into 
pBacPak8 resulting in a plasmid pVGAcCaMDR1 as described in §2.Sf9 cells were co-transfected with wild type Autographa cali-
fornica nuclear polyhedrosis virus (AcNPV) DNA and pVGAcCaMDR1. The resulting virus was designated as vAcCaMDR1. 
(b) Southern hybridization of DNA extracted from Sf9 cells infected with the wild type virus, AcNPV (lanes1 and 2) and recombi-
nant virus vAcCaMDR1 (lanes 3 and 4). Lanes 1 and 3 contain DNA digested with Sal1 and lanes 2 and 4 contain DNA double 
digested with Sal1 and Kpn1. Lane 5 contains 2×1 kb EcoRV fragment of CaMDR1 containing the ORF which was also used as a 
probe for hybridization. 
 
(b) (a) 
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the drug was effluxed out from the insect cells expressing 
CaMdr1p within first 15min. However, at later time 
points due to MTX induced cytotoxicity to insect cell , 
the level of drug accumulation decreased even in the  
control cells. Between the two drugs, MTX efflux was 
very rapid (low accumulation) suggesting it to be a  
preferred substrate of CaMdr1p (figure 2a, b). ABC type 
of drug transporters have earlier been overexpressed in 
baculovirus expression system, but virus infected intact 
insect cells could not be used to ascertain if expression 
led to MDR phenotype because post infected cells are 
prone  to viral-induced lysis (Germann 1998; Krishna-
murthy et al 1998b). As an alternative, membrane  
vesicles of insect cells were used to study drug  
transport and drug protein interactions. Hence, this  
is the first report where we could use intact Sf9  
insect cells over expressing CaMDR1 to study drug  
transport. 
  
3.3 FLC and MTX binding sites in CaMdr1p  
do not overlap 
Further studies pertaining to the kinetics and specificity of 
CaMdr1p expressed in insect cells could not be performed 
because of drug toxicity. In order to circumvent this prob-
lem, CaMdr1p was expressed in a hypersensitive S. cere-
visiae strain. As shown in figure 3a and figure 4a, host  
 
Figure 3. Kinetics of [3H]FLC accumulation i  yeast JG436 
transformed with CaMDR1. (a) Time course of [3H]FLC trans-
port Mid log phase yeast cells JG436 and JGCaMDR1 were 
incubated with 100 nM of [3H]FLC for 60 min as described in 
§ 2. (b) Specificity of FLC transport mediated by CaMdr1p. 
Competition of [3H]FLC transport in JGCaMDR1 cells was 
measured in the presence of 100-fold excess of cold drugs as 
described in § 2. Energy inhibitors Van, sodium orthovanadate 
and Azide were added to the cells at a concentrati  of 100 mM 
and 10 mM respectively. The accumulation of [3H]FLC in yeast 
cells was measured and compared at 30 min time interval. The 
bar in each figure shows standard deviation and values are the 
means of three independent experiments. 
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Figure 2. Drug transport mediated by CaMdr1p in Sf9 cells. 
(a) FLC transport mediated by CaMdr1p in Sf9 insect cells at 
48 h post infection was done as described in § 2. Briefly ( ) 
wild type AcNPV and ( ) vAcCaMDR1 virus infected Sf9 cells 
were incubated in the presence of 100 nM of [3H]FLC for vari-
ous time points up to 60 min. Cells from each time point were 
washed with PBS and radioactivity associated with the cells was 
measured. (b) Time course of [3H]MTX transport. Cells were 
incubated in the presence of 25 mM [3H]MTX. The uptake of 
MTX was done as described above for FLC. The results are 
average of 3–4 separate experiments where variation was less 
than 5%. 
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JG436 showed enhanced accumulation of [3H]FLC and 
[3H]MTX with time, while the transformant expressing 
CaMDR1 showed reduced accumulation of both the 
drugs. 
 As mentioned earlier CaMDR1 confers resistance to a 
variety of unrelated drugs implying that these drugs could 
also be transported by this transporter (Gupta et al 1998; 
Sanglard et al 1996). Therefore, in order to check the 
specificity of CaMdr1p mediated drug transport, the  
accumulation of MTX and FLC was followed either alone 
or in presence of high concentration of other drugs. In 
the following experiments, JGCaMDR1 cells were pre-
incubated with 100-fold concentrations of MTX, FLC, 
CYH and BEN before assaying for drug accumulation as 
described in § 2. Interestingly, the excess MTX did not 
affect the accumulation of FLC. The accumulation of 
MTX also remained unaffected by high concentration of 
FLC (figures 3b and 4b). For all such experiments, a  
parallel control experiment was performed in S. cerevisiae 
host JG436, in which no marked difference in the levels 
of accumulation of radiolabelled drugs was observed upon 
incubation with excess cold drugs (data not shown).
Therefore, while CaMdr1p transports both the drugs, the 
binding sites for MTX and FLC in CaMdr1p appeared to 
be distinct. The excess of BEN on the other hand could 
block the efflux of both MTX and FLC, which suggested 
that its binding to CaMdr1p overlaps with that of two 
drugs. Interestingly, CYH did not interfere with the efflux 
of either of the drugs, indicating that it had discrete bin-
ing sites. The efflux of both the drugs mediated by 
CaMdr1p was energy dependent as it could be inhibited 
by sodium orthovanadate and sodium azide (figures 3b 
and 4b). 
 In another experiment we observed that MTX which 
was a substrate for CaMdr1p, could not be transported by  
 
Figure 4. Kinetics of [3H]MTX accumulation in yeast JG436 
transformed with CaMDR1. (a) Time course of [3H]MTX trans-
port. Mid log phase yeast cells JG436 and JGCaMDR1 were 
incubated with 25 mM [3H] of MTX for 180 min as described in 
§ 2. (b) Specificity of MTX transport mediated by CaMdr1p. 
Competi ion of [3H]MTX transport in JGCaMDR1 cells was 
measured in the presence of 100-fold excess of cold drugs as 
described in legend to figure 3b. 
 
(a) 
(b) 
Table 1. Susceptibility of yeast and its MDR transforma ts to antifungal agents.       
MIC ( mg ml–1) 
 
 
 
Strains 
 
 
  Genotype FLC MTX CYH BEN             
JG436* Dpdr5a  2 3×12 0×019 10 
JGCDR1 Dpdr5 + CDR1 32 3×12 0×156 10 
JGCaMDR1 Dpdr5 + CaMDR1  8 12.0 0×156 10             
MIC were determined by microtite  plate assay as described in § 2 (Talibi and Raymond 
1999). For MTX, sulphanilamide was added to the media at a concentrion of 200 mg ml–1. 
Cells were grown for 48 h at 30°C to obtain single colonies which were resusp nded in a 0×9% 
normal saline solution to give an optical density at 600 nm (OD600) of 0×1. The cells were then 
diluted 100-folds in SD–URA media. The diluted cell suspensions (100-folds) were added to 
round bottomed 96-well microtiter plates (100 ml/well) in wells containing equal volumes of 
medium (100 ml/well) with different concentrations of drugs. End point was read at OD620 
after 48 h incubation of plates at 30oC. 
aPDR5 has been disrupted in this strain (see § 2). 
*The relative drug sensitivity of vector transformed JG436 cells did not show any variations as 
compared to non transformant JG436 cells. 
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Cdr1p an ABC protein also involved in azole resistance in 
C. albicans when expressed in similar host background 
(data not shown). The selectivity of the pump was further 
evident from microtitre plate assay where it was observed 
that JGCDR1 (harbouring CDR1) had a higher MIC value 
for FLC but was hypersensitive to MTX (table 1). It is 
notable that MTX could strongly enhance the expression 
of CaMDR1 while it had no effect on CDR1 expression 
(Gupta et al 1998). That MTX is not a substrate of ABC 
proteins was also supported by previous observations by 
De Graaf et al (1996) where MTX resistance of a cell  
was shown to be distinct from MDR mediated by  
P-glycoprotein (P-gp). MTX which inhibits dihydrofolate 
reductase, is hydrophilic in nature and is only removed
from the cells by P-gp when under certain conditi s 
MTX enters cells via membrane. Our results show that 
Cdr1p, which poorly transports MTX, is a structural and 
functional homologue of P-gp, thus illustrating the con-
servation of functions down the evolutionary scale.  
 It is becoming increasingly evident from mammalian 
ABC transporters that they harbour discrete drug binding 
domains that are clustered for some drugs and scattered 
over the entire protein for some other drugs (Gottessmann 
and Pastan 1993; Ambudkar and Gottesman 1998). 
Cdr1p, an ABC transporter of C. albicans has also been 
shown to posses distinct drug binding sites at its C termi-
nal (Krishnamurthy et al 1998b). The deletion of 79 aa 
from its C-terminal encompassing TM12 could lead to 
hypersensitivity to several drugs, while the truncated pro-
tein could still confer resistance to drugs like FLC. In this 
study we have shown for the first time that CaMdr1p also 
has different drug binding sites. Preci e knowledge of the 
mechanism by which transporters recognize their sub-
strates might have important clinical implications. Under-
standing antifungal resistance in general and the 
specificity of drug transport (this study) in particular is 
important for the improved management of C. albicans 
infection.  
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